Clinical Trials Logo

Advanced Kidney Cancer clinical trials

View clinical trials related to Advanced Kidney Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05485896 Recruiting - Clinical trials for Advanced Kidney Cancer

Pembrolizumab Plus Lenvatinib in Stage III-IV RCC

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer. Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles pre-operation and patients need to continue taking the drug for a year after surgery.

NCT ID: NCT05485883 Recruiting - Clinical trials for Advanced Kidney Cancer

Tislelizumab Plus Lenvatinib in Stage III-IV RCC

TILUR
Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects

NCT ID: NCT03540199 Withdrawn - Clinical trials for Advanced Kidney Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Start date: April 10, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced kidney cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for kidney cancer.

NCT ID: NCT03308396 Active, not recruiting - Kidney Cancer Clinical Trials

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Start date: December 19, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have received 0-1 prior therapy but no prior anti-PD-1/PD-L1/CTLA4 (Cohort 1, 36 subjects). Study treatment could potentially continue for up to 13 cycles (52 weeks).